Table 2.
Evidence of drug interactions from two‐dimensional chequerboard testing of tamoxifen in combination with either amphotericin, fluconazole or flucytosine
| Antifungal combination | Proportion (%) of isolates where particular drug interactions was observeda | ||
|---|---|---|---|
|
Synergy FICI ≤ 0.5 |
No interaction 0.5 < FICI ≤ 4 |
Antagonism FIC > 4 |
|
| Cryptococcus neoformans | |||
| Tamoxifen + amphotericin | 67 (20/30) | 33 (10/30) | 0 (0/30) |
| Tamoxifen + fluconazole | 5 (1/20) | 95 (19/20) | 0 (0/20) |
| Tamoxifen + flucytosine | 0 (0/20) | 100 (20/20) | 0 (0/20) |
| Cryptococcus gattii sensu lato b | |||
| Tamoxifen + amphotericin | 75% (6/8) | 25% (2/8) | 0 (0/8) |
a
Numbers in brackets: Numerators are the numbers of strains where interaction was observed; denominators are the numbers of isolates tested.
b
Includes data from four Vietnamese clinical isolates (three C. gattii sensu stricto and one C. deuterogatii, and the four control strains).